Merck Sharp + Dohme Corp.

H. Lundbeck A/s

Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa

Daniel J Kumke

Feng Xu

Kevin Michael Belyk

Hsien-Hsin Tung

Bryon Ladd Simmons

Amar J Mahajan

Jerry A Murry

Henry G Morrison

Lawrence Wai

Vanessa Pruzinsky

Benjamin Cohen

Philip Jones

Vincenzo Summa

Philip J Pye

Lushi Tan

Aaron S Cote

Remy Angelaud

Danny Mancheno

V Brett Cooper

Kevin M Belyk

Potassium salts of Compound A and methods for their preparation are disclosed, wherein Compound A is of formula: Compound A is an HIV integrase inhibitor useful for treating or prophylaxis of HIV infection, for delaying the onset of AIDS, and for treating or prophylaxis of AIDS.

Process for preparing N-alkylated hydroxypyrimidinone compounds

The present invention relates to a process for the production of crystalline particles of a glucagon receptor antagonist compound. The process includes the steps of generating microseeds and subjecting the microseeds to a crystallization process. The resulting crystalline particles have a mean particle size of less than about 100 mm. The present invention also provides for a pharmaceutical composition which includes the crystalline particles produced by the method described herein and a pharmaceutically acceptable carrier.

Process for the production of a crystalline glucagon receptor antagonist compound

The present invention is directed to novel polymorphic forms of the compound 4,5,6,7-tetrahydroisoxazolo[5,4-c]pyridin-3-ol hydrate (gaboxadol monohydrate). The invention is further concerned with pharmaceutical compositions containing the polymorphic forms as an active ingredient, methods for treatment of disorders susceptible to amelioration by GABAA receptor agonism with the polymorphic forms, and processes for the preparation of the polymorphic forms.

Polymorphic forms of a GABAA agonist

[object Object]

Potassium salt of an HIV integrase inhibitor

Growing community of inventors

Colts Neck, NJ, United States of America

Daniel J Kumke